Goal-directed hemostatic resuscitation based on thrombelastography (TEG) has a survival benefit compared with conventional coagulation assays such as international normalized ratio, activated partial thromboplastin time, fibrinogen level, and platelet count. While TEG-based transfusion thresholds for patients at risk for massive transfusion (MT) have been defined using rapid TEG, cutoffs have not been defined for TEG using other activators such as kaolin. The purpose of this study was to develop thresholds for blood product transfusion using citrated kaolin TEG (CK-TEG) in patients at risk for MT.
xsanguination from uncontrolled hemorrhage is the leading cause of preventable death after trauma, accounting for up to 40% of deaths, half of which occur within the first 2 hours. 1, 2 An endogenous trauma-induced coagulopathy contributes to the majority of hemorrhagic deaths and is a multifocal process attributed to reduced thrombin generation, fibrinogen depletion, platelet dysfunction, systemic hyperfibrinolysis, and fibrinolysis shutdown. [3] [4] [5] [6] [7] [8] The implementation of massive transfusion protocols (MTPs) improve survival in the treatment of patients in hemorrhagic shock. 2, [9] [10] [11] [12] 13 Significant resources have been directed toward identifying the ideal ratio of blood products in resuscitation. 2, 9, 11 Although ratio-based resuscitation may be appropriate in the initial stages of managing the critically injured, subsequent blood component has traditionally been guided by conventional coagulation assays such as the international normalized ratio (INR) of the prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen level, and platelet count. 10 Through the use thrombelastography (TEG), a viscoelastic assay that provides comprehensive assessment of clot formation and clot degradation, our group have shown that a goal-directed MTP guided by TEG improves survival compared with MTP guided by conventional coagulation assays. Furthermore, this improved survival is accomplished with the transfusion of fewer plasma and platelet units during the early phases of resuscitation of the injured patient.
We have previously used rapid TEG (rTEG) to define optimal transfusion thresholds that are used to guide hemostatic resuscitation for patients at risk for massive transfusion (MT). These defined thresholds include transfusion of plasma for an activated clotting time (ACT) <128 seconds, transfusion of cryoprecipitate for an angle <65 degrees, transfusion of platelets for a maximum amplitude (MA) <55 mm, and administration of antifibrinolytics for a LY30 >5%. 9 However, these thresholds are not directly translatable for use in TEG with other activators such as kaolin alone (citrated kaolin TEG), 14 which is used by some centers to guide hemostatic resuscitation. The type of activator differentiates rTEG from other activated TEGs (citrated kaolin TEG). Rapid TEG is activated with tissue factor and kaolin whereas citrated kaolin TEG (CK-TEG) is activated only with kaolin.
14 Although activated TEG (with either tissue factor or kaolin) enhances clotting and speeds the time to completion of the assay, there are potential mechanistic limitations to using rTEG. The use of tissue factor in rTEG may overwhelm endogenous clot activation and mask native circulating factors that promote clot formation after trauma. 5 Indeed, it is likely that TEG initiated by kaolin may (as a result of a more subtle activation) prove superior at evaluating hypercoagulable patients, whereas rTEG may be better to evaluate hypocoagulable patients. Consequently, our objective was to identify coagulation abnormalities, identified as a need for massive transfusion (a surrogate for significant coagulopathy), for each CK-TEG parameter of clot formation and breakdown and use these parameters to define thresholds to guide hemostatic resuscitation for patients at risk for massive transfusion.
METHODS

Study Design
This is an analysis of prospectively collected data from adult (age ≥ 18 years) trauma activation patients who met criteria for the highest-level trauma activation (see Document, Supplemental Digital Content 1, http://links.lww.com/TA/B190) at the Denver Health Medical Center (DHMC) and Zuckerberg San Francisco General Hospital (ZSFGH) between 2010 and 2017. Both centers are American College of Surgeons-verified and state-certified Level 1 trauma centers. Exclusion criteria were unsalvageable injuries (defined by patients in asystole at emergency department [ED] arrival), isolated gunshot wounds to the head, pregnancy, incarcerated patients, transferred from another hospital, documented chronic liver disease, or a known coagulation disorder.
Samples were obtained under protocols approved by the institutional review board for each institution. The studies contributing to this database were approved by the Colorado Multiple Institution Review Board under a waiver of consent for Denver Health. Informed consent was obtained for all patients at ZSFGH under a protocol approved by the Committee on Human Research at University of California, San Francisco. Trained research professional assistants performed all viscoelastic assays within 1 hour postinjury. Clinicians were blinded to research data.
Massive transfusion activation was under physician discretion. The transfusion of products other than red blood cells (RBCs) during this period was guided by rapid thrombelastography (rTEG) criteria, as previously described at DHMC. 10, 15 For this protocol, 4 units of RBC and 2 plasma units were delivered to the patient's bedside. These first units were administered according to the treating clinicians' criteria while awaiting results of rTEG. 10 A non-protocolized transfusion protocol, based on clinical evaluation and conventional coagulation assays, was employed at ZSFGH as previously described. 16 However, if patients at ZSFGH was resuscitated in the trauma operating room, a rotational thromboelastometry (ROTEM)-based MTP was initiated that transfused plasma for an EXTEM CT >80 seconds, cryoprecipitate or fibrinogen products for a FIBTEM MCF <8 mm, platelets for an EXTEM MCF <45 mm and a FIBTEM MCF >10 mm, and tranexamic acid for an EXTEM ML >10%. The primary outcome of this study was MT, defined as >10 units of RBCs or death in first 6 hours from injury based on findings previously published by our group 17 to account for survivor bias. This endpoint was used to define thresholds for blood component therapy in massively transfused patients.
Citrated kaolin TEG (CK-TEG)
Citrated kaolin TEG (CK-TEG) was performed on whole blood collected in citrated vacuum tubes to prevent clotting before assays. CK-TEG assays yield the following parameters to assess the dynamic process of clot formation and breakdown in this study: 
Conventional Coagulation Assays (CCA)
Samples were collected during trauma activations upon arrival to the ED in tubes containing 3.2% citrate and 4 mL of heparin (19 U/mL). Values for conventional coagulation assays (INR and aPTT) were determined by the clinical laboratory at DHMC and ZSFGH by standard protocol.
Statistical Analysis
GraphPad Prism version 7.0a (GraphPad Software, Inc., La Jolla, CA) and Excel version 12.2.5 (Microsoft Corporation, Redmond, WA) were used for statistical analysis. For nonnormally distributed variables, data were expressed as median and interquartile range (IQR) using a two-tailed MannWhitney test. Area under the receiver operating characteristic (AUROC) curve analysis was performed for each CK-TEG measurement to assess its predictive performance for massive transfusion. For each of the CK-TEG measurement, we selected the thresholds with the strongest differentiation of the outcome (MT) as identified by the maximum Youden Index (J = sensitivity + specificity − 1). The maximum Youden's Index is the value closest to 1. 21 The sensitivity, specificity, positive, and negative predictive values were also determined for CK-TEG variables, INR, and aPTT.
RESULTS
There were 825 patients who had CK-TEG performed on presentation. The demographic characteristics of these patients are summarized in Table 1 . Of the patients included, 671 (81.3%) were men, 419 (50.8%) patients suffered a blunt injury, and 62 (7.5%) received a MT. Patients who had a MTwere more severely injured, had signs of more pronounced shock, had more abnormal conventional coagulation assay values, and had more abnormal CK-TEG parameters compared with those who did not require MT (Tables 2 and 3 ). Of the 763 who did not receive a MT, 191 (25%) received 1 or more units of RBC with a median of 3 units (IQR 2-5 units). Furthermore, the characteristics of MT patients between centers are shown in Table 4 . Patients included from the Denver database had increased signs of shock (lower systolic blood pressure, elevated lactate, increased base deficit) as well as some more abnormal coagulation studies (increased LY30 and longer INR) when compared with the San Francisco database.
The AUROC for CK-TEG parameters are shown in Table 5 . Of all CK-TEG parameters that measured dynamics of clot formation, CK-TEG MA was the best predictor of MT (AUROC = 0.74, 95% CI 0.67 to 0.82, p < 0.0001).
The optimal thresholds for the CK-TEG-guided MT based on the Youden Index are shown in Table 6 and Figure 1 .
Predictive capacity of each CK-TEG thresholds measured is shown in Table 6 .
DISCUSSION
In this study, we determined the degree of discrimination offered by CK-TEG parameters for MT. Whereas most centers that use TEG employ rTEG for MT, others continue to use CK-TEG. Based on the CK-TEG parameters evaluated, thresholds were identified that could be used to guide hemostatic resuscitation for injured patients who receive a MT. Based on these, we propose plasma transfusion for R-time >4.45 min, fibrinogen products for an angle <67 degrees, platelet transfusion for MA <60 mm, and antifibrinolytics for LY30 >4.55% (Fig. 1) . The CK-TEG is an assay that is activated with the use of kaolin, which stimulates coagulation through the intrinsic or contact pathway. Various methods for restoring and maintaining normal hemostasis have been described including ratio-based transfusion or goal-directed therapy with viscoelastic-based transfusions. Goal-directed therapy is used to optimize a normal hemostatic competence until this hemostasis is obtained and has been shown to improve survival. 22 When using different TEG assays, measurements cannot be generalized, as activators (e.g., tissue factor, kaolin, or endogenous contact to surface of assay cup) differ between these tests. 23 One study has shown that the results of conventional coagulation tests correlate moderately with rTEG parameters, and these rTEG parameters correlate strongly with the most aspects of the respective kaolin TEG parameters. 24 Furthermore, rTEG and CK-TEG show comparable predictive capacity in patients who receive a blood transfusion. 24 In this study, we found the CK-TEG parameters that yielded the greatest AUROC curves were the angle (AUROC = 0.6931) and MA (AUROC = 0.7425). These parameters have routinely been shown to produce the greatest AUROC in studies evaluating ROTEM and rTEG, 9, 24, 25 indicating that clot strength and dynamics of clot strength have the best predictive capacity for MT. Clot initiation (R-time), however, had poor predictability of MT (AUROC = 0.6002). This is consistent with previous studies that have shown that measures of clot initiation do not have a strong correlation with transfusions. 26 A poor correlation between rTEG and CK-TEG measures of clot initiation further supports the notion that clot initiation is an inconsistent predictor of MT. 24 Other factors besides just coagulation factors may also influence clot initiation and include the effects of fibrinolysis and genetic variability. 27, 28 Finally, as proteomic analysis of individual patients becomes more accessible, changes in plasma proteins in response to injury may also show to be directly influential toward clot initiation and subsequent laboratory tests used to identify abnormalities in this aspect of blood clotting. 29 The CK-TEG parameter for fibrinolysis, LY30, also yielded a suboptimal AUROC curve of 0.6024. This finding is consistent with evaluation of other viscoelastic assays that had suboptimal AUROC curves for markers of fibrinolysis.
9,30 Extent of fibrinolysis and early mortality exhibit a quadratic relationship, which may be responsible for the diminished ability of viscoelastic measurements of fibrinolysis to predict massive transfusion. 31 The exact nature of this quadratic relationship is difficult to discern. The quadratic relationship refers to a U-shape in which mortality is increased on either of the extreme. We found the same complexity in assessing FFP/RBC ratios in previous studies. 17 The value of TEG is in identifying specific mechanistic perturbations of coagulation and therefore guiding specific blood component resuscitation. Our goal was to determine CK-TEG thresholds that predict MT (a surrogate for significant coagulopathy) for the purpose of use in goal-directed resuscitation. The thresholds illustrated in Figure 1 reflect proposed points at which administration of specific blood products should be initiated for CK-TEG. It is important to consider the type of viscoelastic assay that is used for the treatment of the bleeding injured patient. TEG is used at our institution and more commonly in the United States, whereas ROTEM is prominently used in European centers. 14 Not only are there different Table illustrates the AUROC with 95% confidence intervals of CK-TEG parameters for each aspect of clot formation and breakdown (clot initiation, dynamics of clot formation, clot strength, and fibrinolysis or clot breakdown). Clot initiation, dynamics of clot formation, clot strength, and fibrinolysis are commonly only measured with a single value that is subsequently used clinically, so only the most commonly used parameter is reported for each aspect of clot formation and breakdown. commercially available viscoelastic assay (ROTEM and TEG), but there are different activators for these assays. 14 Similarly, more specialized viscoelastic assays can look specifically at fibrinogen function or platelet function. For example, the FIBTEM assay (ROTEM) and the functional fibrinogen assay (TEG) can address the fibrinogen contribution to cloth strength whereas TEG platelet mapping (TEG-PM) and ROTEM platelet can address the function of platelets in the presence of various platelet agonists. 4, 8, 32, 33 Although the exact use of these specialized assays is still under debate, we have previously described that adenosine diphosphate (ADP) receptor inhibition did not add predictive value in predicting mortality, massive transfusion, or platelet transfusion with TEG-PM. 33 Some consider the rTEG (activated with kaolin and tissue factor) to be more physiologically relevant to trauma, and these combined activators provide results sooner. However, CK-TEG is also used for the treatment of injured patients to guide blood product transfusion and may be better at identifying hypercoaguability as a large multicenter study using tissue factor to activate viscoelastic assays showed that 10% of trauma patients had a hypercoaguable state within 24 hours of admission. 33 The use of tissue factor may subsequently mask endogenous circulating factors that create a hypercoaguable state. 5, 34 As we have shown that resuscitation based on rTEG improves survival compared with conventional coagulation assays, it may not matter which viscoelastic assay (rTEG, CK-TEG, or ROTEM) is used to guide hemostatic resuscitation in injured patients.
There were some important differences seen between the two centers included in the study (Table 4 ). The systolic blood pressure was lower, lactate and base deficit were increased, and INR and LY30 were longer in the Denver massively transfused patients compared with San Francisco. The increased shock could explain the enhanced INR and longer LY30. 35, 36 However, the injury severity, and a majority of the coagulation parameters (fibrinogen, PTT, R-time, angle, and MA) were not different between groups.
There are several limitations notable to this study. These data reflect a single time point of a dynamics process and does not take into account the temporal changes of the coagulation process through the acute phase of resuscitation. It should be noted that rTEG resuscitation was only practiced at one of the centers, which may introduce some variability. Some of these patients received a transfusion based on goal-directed resuscitation based on rTEG, and as such, these CK-TEG thresholds are predictive of a massive transfusion that is already partially guided by viscoelastic testing (rTEG). We acknowledge that these measurements are analyzed for MT as an endpoint and not individual components and should be used cautiously for continued guidance of blood product transfusion. However, at this time, these thresholds provide the best guidelines for specific components and can act as a framework for the refinement of goal-directed CK-TEG-based resuscitation. Furthermore, these data do not evaluate the effects of intervention of blood products on treating patients who received a MT and the study is not designed to define mortality-related outcomes. Finally, as our focus was on MT, we did not evaluate other clottingrelated outcomes such as macrovascular and microvascular thromboembolic events or multiple organ failure.
In conclusion, the proposed thresholds provide an important addition to the evolution of viscoelastic-based resuscitation Figure 1 . Proposed citrated kaolin TEG-guided resuscitation thresholds for patients receiving a massive transfusion. A schematic representation of the proposed thresholds in a CK-TEG-guided MTP for injured patients. These thresholds represent proposed points at which administration of specific blood products should be initiated in the bleeding patient. Cryo, cryoprecipitate; PLTs, platelets; and TXA, tranexamic acid. strategies. Our goal was to identify the best predictor of significant coagulopathy, using MT as a surrogate, for each aspect of the dynamic process of clot formation and breakdown using CK-TEG, a commonly used viscoelastic assay. These initial observations may serve as a building block for a multicenter trial to test the proposed algorithm, refine these recommendations, and compare viscoelastic assays. Refinement of the CK-TEGbased resuscitation strategies should include optimizing the respective clinical interventions for each given CK-TEG parameter to determine if targeting these thresholds will reduce mortality. Although TEG can define which aspect of clot formation and breakdown is abnormal, assays such as proteomic or metabolomic analysis of injured patients may help better define the specific abnormality within clot initiation, dynamics of clot formation, clot strength, or fibrinolysis that accounts for the deranged TEG parameter. AUTHORSHIP G.R.S. and J.J.S. implemented the study, interpreted data, drafted and critically revised the article. G.R.N. interpreted data, drafted and critically revised the article. L.Z.K. interpreted data, drafted and critically revised the article. A.S.C. interpreted data, drafted and critically revised the article. E.E.M., M.J.C., R.A.C., C.C.S., A.B., and A.S. are principal investigators, were responsible for study conception and design, implementation of study, completion of study, interpretation of data, article drafting, and critical revision.
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